R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2803822/0/en/R-D-Day-Highlights-Kymera-s-Immunology-Strategy-and-Emerging-Pipeline-of-Novel-First-in-Class-Oral-Degraders-Addressing-Multiple-Highly-Prevalent-Immuno-inflammatory-Diseases.html

Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential

STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024

Read more at globenewswire.com

Related news for (KYMR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.